Prime Editing Platform: Precise Genome Correction Based on a Cas9 Nickase–Reverse Transcriptase Fusion Protein
-
Genomic noise from double‑strand break (DSB)–induced collapse and the bottleneck in precise genome engineering The third‑generation CRISPR‑Cas9 system, which has driven most of modern genome engineering, is a powerful modality for eliminating the genetic causes of chronic monogenic diseases. However, it is limited by intrinsic molecular constraints. Because the naturally derived Cas9 protein forces a double‑strand break in the target DNA, the ensuing non‑homologous end‑joining (NHEJ) repair pathway generates random insertion–deletion (indel) errors and can trigger large‑scale chromosomal translocation noise with genotoxic potential. Homology‑directed repair (HDR) using exogenous donor DNA becomes inefficient in post‑mitotic adult stem cells or neurons, creating a trade‑off that collapses catalytic efficiency, and it fails to overcome off‑target genome damage, forming a technical bottleneck.
-
Prime editing molecular architecture: computational fusion of a Cas9 nickase and reverse transcriptase In this work we eliminated DSB‑derived cytotoxicity at the source and activated a computationally designed platform that writes arbitrary sequence information directly into the genome. We achieved a physical linkage of a Cas9 nickase and a reverse transcriptase on a single backbone, creating a fusion‑protein platform that operates synchronously with a prime‑editing guide RNA (pegRNA). The pegRNA‑mediated nick on the non‑target strand exposes a 3′‑OH terminus, which hybridizes to the primer‑binding site (PBS) of the reverse‑transcriptase template. The reverse transcriptase then copies the contiguous reverse‑transcriptase template (RTT) sequence, effecting a scar‑free search‑and‑replace edit that accomplishes single‑base substitution, precise insertion, or deletion without genotoxic noise.
-
Kinetic evolution from PE1 to PE7 and optimization of in‑vivo delivery platforms To overcome the low catalytic turnover of the early PE1/PE2 protocols, we engineered successive generations: PE3 adds a second nick on the non‑target strand; PE4/PE5 computationally suppress mismatch‑repair (MMR) pathways; and the latest PE7 maximizes guide‑RNA structural stability. These molecular‑evolutionary upgrades enable scalable, high‑efficiency editing. A twin‑PE system capable of site‑specific knock‑in of >7.1 kb gene cassettes was completed, and delivery was integrated with lipid nanoparticle (LNP) and engineered virus‑like particle (eVLP) frameworks. This combination isolates inter‑generational transcriptomic variance in human induced pluripotent stem cells (iPSCs) to below baseline, establishing a preclinical endpoint for translational studies.
-
Establishing global regulatory standards for programmable therapeutic nucleases This integrated data‑white paper on computational genome engineering and synthetic biology resets the gene‑therapy paradigm from uncertain post‑DSB repair to a "designed reverse‑transcriptase‑derived programmable pin‑point genome‑writing infrastructure." By tuning pegRNA free energy, we built a computational backbone that prospectively calculates CMC (chemistry, manufacturing, and controls) thresholds for agricultural trait improvement and regenerative‑medicine R&D. The defined prime‑editing docking matrix will serve as a standard coefficient to eliminate false‑positive genotoxicity rejections in rare‑disease pipelines of multinational pharmaceutical companies, dramatically shortening IND approval timelines and becoming a master asset for next‑generation precision‑medicine engines.
Nature Biotechnology, Published June 2026.
Summary: Bypassing the intrinsic double-strand break (DSB) liabilities and random indel mutations that inherently bottleneck conventional wild-type CRISPR-Cas9 pipelines, this comprehensive review systemizes the structural translation of Prime Editing (PE) architectures. Operating via a high-performance fusion protein composed of an engineered Cas9 nickase and an optimized reverse transcriptase matched with a prime editing guide RNA (pegRNA), the platform executes search-and-replace edits including precise base substitutions, scarless insertions, and deletions. Tracing the methodological breakthroughs from PE1 up to the hyper-efficient PE7 system, the framework captures the kinetics of twin-PE large-fragment genomic integration alongside non-integrating lipid nanoparticle (LNP) delivery vectors, establishing a predictive, high-throughput computational baseline for universal patient stratification and targeted clinical translation.
The molecular‑genetic discoveries reported here extend beyond theoretical advances to directly power gene‑therapy supply chains and B2B precision‑regenerative‑medicine business lines. First, when correcting chronic dominant‑inheritance disease alleles in patients, prime editing’s non‑cut reprogramming mechanism eradicates off‑target genome damage and genotoxic noise, preserving the long‑term safety profile of one‑shot cell‑therapy (CGT) products. Simultaneously, the four‑amino‑acid‑side‑chain pin‑point substitution technology and large‑cassette kinetic framework, when coupled to LNP delivery, completely overcome the immunogenicity barriers associated with viral vectors and optimize intracellular internalization kinetics in target tissues. Moreover, during large‑scale regulatory submissions for next‑generation rare‑blood and metabolic disease programs, the pegRNA‑binding threshold values derived from genome‑landscape analyses can be used as correction factors to drive batch‑level genotoxicity scores to zero, maximizing IND approval probabilities across global regulatory agencies.